Webinar
2 Mar 2023

How Market Trends Drive Innovation and Enable the Pharmaceutical Pipeline

Our healthcare industry is evolving. The move from IV to SC injection is being driven by lifecycle management, biosimilar adoption, and the hospital to home trend. Molecules are getting more complex, and patients drive the preference for self-administration resulting in the need for more complex combination product development and quick scale up. We will present innovative solutions to these challenges to help speed up drug development and enable patient choice with:

  • A 2.25mL polymer container system for auto-injectors which protects sensitive molecules
  • A large volume cartridge plunger to enable primary containment within an on-body delivery system
  • A small pack, high quality glass containment system to enable quick delivery in early-stage development

Content provided by our supplier

West Pharmaceutical Services, Inc.

  • US
  • 2017
    On CPHI since
  • 4
    Certificates
  • 5000+
    Employees
Company types
Drug delivery device Supplier/Manufacturer
Manufacturer/Innovator
Packaging supplier/manufacturer
Primary activities
Contract Manufacturer
Laboratory Services
Medical Devices
Packaging & drug delivery
Regulatory Affairs
View company profile

Other Content from West Pharmaceutical Services, Inc. (3)

  • West Collaborates with Corning for Sustainable Drug Delivery

    News West Collaborates with Corning for Sustainable Drug Delivery

    West and Corning Launch Viridian™ Vials that provide both performance and sustainability to the healthcare industry
    26 Sep 2023
  • Examining Contamination Control Strategy in Primary Packaging as Part of EU GMP Annex 1

    Video Examining Contamination Control Strategy in Primary Packaging as Part of EU GMP Annex 1

    There are two major themes that involve primary packaging components in the revised EU GMP Annex 1 issued in August 2023. This recent revision includes: Implementing a holistic Contamination Control Strategy (CCS) Container Closure Integrity (CCI) because a properly seated stopper represents an adequate microbiological barrier. Pharmaceutical manufacturers must develop a CCS detailing the risks and mitigations within their operations, associated with contamination event opportunities with the emphasis being on personnel awareness, quality culture and controls, with focus on the principles involved in the protection of sterile product during the manufacturing, packaging and distribution processes.
    This is why it is important to consider packaging decisions early in the development process. We will examine how primary packaging materials can impact your CCS and showcase West’s approach to mitigating risk on behalf of drug developers.
    2024-10-23
  • Design of a New Elastomer Formulation for Lyophilization Applications

    Webinar Design of a New Elastomer Formulation for Lyophilization Applications

    4040/40 elastomer formulation was designed with ‘future in mind’ to meet the ever-increasing performance & quality standards expected of primary drug packaging. The presentation will summarize the extensive Quality by Design (QbD) process that was undertaken to develop this new formulation as well as considerations taken for closure design dedicated for Lyophilization applications. Details of the extensive characterization that was performed as part of product development as well as data to demonstrates the overall performance of the new rubber formulation for lyophilization stoppers with respect to Extractables/Leachables, Particulates, Moisture, Container Closure Integrity (CCI), Particles and Manufacturability will be presented.
    2023-03-02